#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marginal zone lymphoma recurrent Leber's congenital amaurosis Neuropathy peripheral Immune thrombocytopenia Urea cycle disorder Andersen-Tawil syndrome White matter lesion Phenylketonuria Thromboangiitis obliterans Antiphospholipid antibodies IgA nephropathy Usher's syndrome Primary amyloidosis Kearns-Sayre syndrome Fibrodysplasia ossificans progressiva More trials…

    Learn about Rare Diseases

    Adrenocortical carcinoma Angelman’s syndrome Medulloblastoma – Diagnostics Synovial sarcoma – Treatment Prolymphocytic leukaemia – Treatment Alagille syndrome Hyperoxaluria – Life with Disease Glomerulonephritis rapidly progressive – Treatment Acquired haemophilia Haemophilia B with anti factor IX More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Progesterone Op-1250 Reboxetine Acetylcysteine 19Cp02 Protrans Azd2693 Sodium VAMIFEPORT TRIHYDROCHLORIDE Pertuzumab Ucp4 Messenger Rna Encoding Cas9 Pentixafor Gallium Ga-68 Rintatolimod Acemetacin VELPATASVIR Glucocorticoids Carvedilol Betula Alba Pollen Extract AZD0292 Jab-21822 More therapies…

    Learn about Your Condition

    Type V hyperlipidaemia Haematological malignancy Colon cancer stage III Procedural headache Osteosarcoma recurrent Radiation skin injury Partial lipodystrophy Microscopic polyangiitis Tertiary adrenal insufficiency Intracranial calcification Ebola disease Brain neoplasm malignant Fracture infection Hidradenitis Head and neck cancer stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Long‑term safety of IMA203 and IMA203CD8 autologous T‑cell therapy in patients with previously treated advanced or metastatic solid tumors

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Ima203Cd8
    • AUTOLOGOUS T-CELLS TRANSDUCED WITH THE LENTIVIRAL LV-R11KEA ENCODING T-CELL RECEPTOR TARGETING PATIENT-SPECIFIC TUMOR-ASSOCIATED ANTIGENS
    Germany

  • Safety and tolerability of OV329 as add‑on therapy in adults with drug‑resistant focal epilepsy

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Partial seizures
    The Netherlands

  • Effect of bupropion hydrochloride and mushroom supplement on body weight in overweight adults: a 52‑week randomized trial

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Metabolic syndrome
    • Overweight
    Investigated Drugs:
    • Bupropion Hydrochloride
    Sweden

  • Surgery versus Lauromacrogol 400 injection for superficial labial venous malformations in children and adults: a randomized controlled trial

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Malformation venous
    Investigated Drugs:
    • Lauromacrogol 400
    France

  • Fosfomycin trometamol versus drug combination for treating acute E. coli pyelonephritis in women aged 75 years and older

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Amikacin Sulfate
    • Aztreonam
    • Cefepime
    France

  • A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Polycythaemia vera
    Investigated Drugs:
    • Sapablursen
    Austria Czechia France Germany Hungary Italy +3
Previous Page
1 … 658 659 660 661 662 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!